Investor Presentation H1 2023

136 North America Operations growth has accelerated Investor presentation First six months of 2023 DKK billion 1% 100 60 80 60 60 40 40 20 20 NAO 21% 44% 91 North America Operations reported sales growth per therapy area 3% 14% 67 60 60 61 0 2019 CER: Constant exchange rate 2020 2021 GLP-1 Insulin Other diabetes Obesity care Rare disease 59 H1 2023 Growth at CER 2022

View entire presentation